Jacobs Levy Equity Management
RNAC icon

Jacobs Levy Equity Management’s Cartesian Therapeutics RNAC Stock Holding History

Jacobs Levy Equity Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$624K Buy
101,534
+5,735
+6% +$40.9K ﹤0.01% 786
2025
Q4 		$691K Buy
95,799
+65,798
+219% +$532K ﹤0.01% 747
2025
Q3 		$307K Sell
30,001
-11,316
-27% -$127K ﹤0.01% 879
2025
Q2 		$429K Buy
+41,317
New +$440K ﹤0.01% 904
2023
Q4 		– Sell
-1,083
Closed -$34.4K – 1066
2023
Q3 		$34.4K Sell
1,083
-12,694
-92% -$424K ﹤0.01% 950
2023
Q2 		$463K Sell
13,777
-3,923
-22% -$140K ﹤0.01% 834
2023
Q1 		$738K Sell
17,700
-5,837
-25% -$274K ﹤0.01% 751
2022
Q4 		$798K Sell
23,537
-497
-2% -$21.1K 0.01% 714
2022
Q3 		$1.18M Sell
24,034
-7,012
-23% -$385K 0.01% 674
2022
Q2 		$1.22M Sell
31,046
-5,980
-16% -$177K 0.01% 714
2022
Q1 		$1.37M Sell
37,026
-21,792
-37% -$1.36M 0.01% 702
2021
Q4 		$5.75M Sell
58,818
-8,043
-12% -$865K 0.04% 401
2021
Q3 		$8.34M Sell
66,861
-7,144
-10% -$863K 0.06% 337
2021
Q2 		$9.28M Buy
74,005
+4,639
+7% +$552K 0.06% 311
2021
Q1 		$9.42M Buy
69,366
+33,048
+91% +$4.1M 0.07% 300
2020
Q4 		$3.3M Buy
36,318
+26,581
+273% +$2.3M 0.03% 475
2020
Q3 		$724K Buy
9,737
+1,664
+21% +$127K 0.01% 722
2020
Q2 		$688K Buy
8,073
+6,886
+580% +$624K 0.01% 736
2020
Q1 		$86K Buy
+1,187
New +$115K ﹤0.01% 963
2019
Q1 		– Sell
-2,775
Closed -$221K – 1027
2018
Q4 		$221K Buy
2,775
+216
+8% +$49.3K ﹤0.01% 856
2018
Q3 		$1.19M Buy
2,559
+20
+0.8% +$8.04K 0.02% 619
2018
Q2 		$1.01M Buy
+2,539
New +$901K 0.02% 663

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's RNAC Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Cartesian Therapeutics (RNAC) stake by 6% in Q1 2026, buying an estimated $40.9K and bringing the position to 101,534 shares worth $624K. The position accounts for ﹤0.01% of the portfolio, ranked #786.

Jacobs Levy Equity Management first reported a position in RNAC in Q2 2018 and has held it in 22 quarters since. The position peaked at $9.42M in Q1 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Jacobs Levy Equity Management held 101,534 shares of Cartesian Therapeutics worth $624K as of Q1 2026.
  • Jacobs Levy Equity Management bought 5,735 Cartesian Therapeutics shares in Q1 2026, an estimated $40.9K.
  • Cartesian Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #786 holding.
  • Jacobs Levy Equity Management first reported a position in Cartesian Therapeutics in Q2 2018 and has held it in 22 quarters since.
  • Jacobs Levy Equity Management's Cartesian Therapeutics position peaked at $9.42M in Q1 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.